Consult Lhasa, a wholly owned subsidiary of Lhasa Limited, has been launched to provide expert scientific risk assessments to the pharmaceutical industry. This launch marks a significant milestone in Lhasa Limited commitment to enabling informed decision-making on chemical safety.
Lhasa Limited, a not-for-profit charity, achieves its purpose by creating innovative software solutions in collaboration with industry and regulatory bodies. Lhasa solutions provide trusted predictions that meet global regulatory requirements when combined with expert review.
Aligned with the Lhasa purpose, Consult Lhasa will deliver scientific risk assessments globally, positively impacting human health. Specifically, Consult Lhasa will utilise Lhasa software and knowledge to make decisions on chemical safety, educate others, and directly provide scientific risk assessments to the pharmaceutical industry.
“For many years, our Lhasa members have asked us to provide consultancy services directly”, says Dr Crina Heghes, Consult Lhasa CEO. “This is a great opportunity to apply the knowledge, developed within Lhasa Limited over the last 40 years, to support scientists and positively impact human health”.
Initially, Consult Lhasa is providing risk assessments across four key areas:
- Impurity formation: Enhancing the definition of impurity profiles for active pharmaceutical ingredients (APIs) and drug products.
- Potentially mutagenic impurities: Improving computational assessment and control of potentially mutagenic impurities (PMIs).
- Nitrosamines: Facilitating comprehensive nitrosamine risk assessment profiles.
- Non-mutagenic impurities: Supporting the assessment and control of non-mutagenic impurities.
Watch the video below, featuring Dr Crina Heghes, Consult Lhasa CEO, to learn more.
Discover how Consult Lhasa can improve your scientific risk assessments; contact Consult Lhasa today for a free expert consultation.
